We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Eurofins Genomics and AmpTec Close Distribution Agreement

Eurofins Genomics and AmpTec Close Distribution Agreement

Eurofins Genomics and AmpTec Close Distribution Agreement

Eurofins Genomics and AmpTec Close Distribution Agreement

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eurofins Genomics and AmpTec Close Distribution Agreement"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eurofins Genomics and AmpTec have agreed on non-exclusively co-marketing AmpTec's IVT-RNAs globally.

The co-marketing agreement for IVT ssRNAs, dsRNAs and mRNAs includes RNAs up to several thousand bases and a wide range of modifications.

All nucleic acid products are offered at research grade in compliance with regulations of ISO13485 and at Good Manufacturing Practice (GMP) grade on request, in order to assure highest product quality and regulatory compliance.

The partnership will deliver premium synthetic ssRNAs, dsRNAs and mRNAs that are widely used in a variety of applications from in vitro diagnostics of pathogens and detection of rare gene mutants to the rapidly growing field of companion diagnostics.

Together, the two companies will serve an international market with their combined custom services for synthetic genes and for very long synthetic RNAs.

"The cooperation will allow us to broaden Eurofins' portfolio with innovative nucleic acid products. By sharing best practices, clients will benefit from an unparalleled spectrum of custom services for IVT-RNAs, which in turn should fuel further market share growth for both partners.", says Bruno Poddevin, Senior Vice-President Eurofins Genomics.

"Eurofins' broad expertise in nucleic acid chemistry is a perfect fit for our RNA technology portfolio", says Guido Krupp, President of AmpTec. "Eurofins' emphasis on direct and flexible interaction is very important for us" confirms Peter Scheinert, CSO of AmpTec. "With this agreement, our long-term partnership will reach new levels of market awareness and international recognition."